Introduction {#s1}
============

Smoking during pregnancy is well established as one of the most modifiable risk factors for adverse pregnancy and infant related health effects \[[@C1]\], with effects related to infant birth size including increased risk of low birthweight, length and head circumference \[[@C2], [@C3]\], ponderal index \[[@C3]\] and being small for gestational age (SGA) \[[@C4]--[@C6]\]. Nonlinear decrease in mean adjusted birthweight has been observed with increasing number of cigarettes smoked per day during pregnancy \[[@C7], [@C8]\]. Tobacco exposure may influence fetal growth throughout pregnancy, with small but significant reductions in head size and femur length in the first trimester, reduced growth after the first trimester \[[@C9]\] and selective reduction in abdominal circumference and muscle mass in fetuses exposed in the last trimester \[[@C10]\]. However, it is unclear whether these findings may be extended to smokeless tobacco.

The use of snus, a smokeless tobacco product also known as moist snuff, and other smokeless nicotine products such as electronic cigarettes have increased in recent years \[[@C11], [@C12]\], paralleling decreased smoking rates among young women in many countries \[[@C13]\]. A similar increased use of snus in women of reproductive age in Norway and Sweden \[[@C12], [@C14]\] is also shown during pregnancy \[[@C14], [@C15]\]. We recently showed in the Preventing Atopic Dermatitis and Allergies in Children (PreventADALL) study that 11.3% of pregnant women reported use of any tobacco or nicotine products by 34 weeks of pregnancy; most commonly as snus only in 6.5%, followed by cigarette smoking only in 4.1% and dual smoking and snus in \<1%. Most women stopped snus use or cigarette smoking early in pregnancy, usually within pregnancy week six \[[@C16]\]. Nicotine from snus readily crosses the placenta into the fetal compartments and, together with its metabolites such as cotinine, concentrates in fetal blood, urine, meconium and amniotic fluid \[[@C17], [@C18]\]. Despite substantial documentation in animal models showing adverse effects in the offspring of nicotine exposure by the pregnant female, there are few studies to verify these findings in humans \[[@C19], [@C20]\]. Exposure to snus during pregnancy increased the risk of preterm birth \[[@C21]\], stillbirth \[[@C22], [@C23]\], oral cleft malformation \[[@C24]\] and neonatal apnoea \[[@C25]\] in Swedish Medical Birth Register studies, while altered infant heart rate variability was observed in a prospective observational study \[[@C26]\]. While a study from India showed an average of 87 g reduced birthweight (adjusted for gestational age) in infants born to women who used smokeless tobacco regularly in pregnancy \[[@C27]\], no significant effect of snus use was observed on birthweight in the Swedish registry study \[[@C28]\]. Thus, the effect of snus on birthweight is unclear, nor are we aware of studies assessing potential effects of snus use on other infant size measures at birth \[[@C19]\].

Therefore, we aimed to determine if maternal use of snus in pregnancy might affect infant anthropometric and proportional size measures at birth.

Subjects and methods {#s2}
====================

Study design {#s2a}
------------

This study is based on the large population-based, prospective mother--child birth cohort PreventADALL \[[@C29]\], enrolling 2697 women with 2701 pregnancies and their 2397 infants born at a gestational age of ≥35.0 weeks without serious neonatal disease. The main objectives of the PreventADALL study are to determine whether primary prevention of allergic diseases is possible through a 2×2 factorially designed, randomised trial of two interventions. Additionally, early life exposures and factors involved in allergic diseases and noncommunicable diseases are assessed. Pregnant females were recruited at the routine ultrasound screening at second trimester between gestational weeks 16 and 22, in hospitals from the general, nonselected population from the greater area of Oslo and southeast Norway as well as from the Stockholm area in Sweden between December 2014 and October 2016 \[[@C29]\]. Details of recruitment, inclusion and exclusion criteria are given in the [supplementary material](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00255-2019.figures-only#fig-data-supplementary-materials).

The present study included all 2313 mother--child pairs with available exposure data of any type of nicotine or tobacco product from electronic questionnaires at 18 and/or 34 weeks of pregnancy and whose included singleton newborn babies had anthropometric measurements performed at birth ([supplementary figure S1](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00255-2019.figures-only#fig-data-supplementary-materials)).

Maternal written consent was obtained upon primary enrolment and signed by both parents at newborn inclusion. The PreventADALL study was approved by the regional committees for medical and health research ethics in South-Eastern Norway (2014/518) and in Sweden (2014/2242-31/4).

Subjects {#s2b}
--------

Baseline characteristics among the included and the excluded study participants were similar, except for marital status, previous smoking history and gestational age at birth as shown in [supplementary table S1](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00255-2019.figures-only#fig-data-supplementary-materials).

Methods {#s3}
=======

From electronic questionnaires completed by the women at 18 and 34 weeks of pregnancy, we collected detailed information about snus, cigarette smoking, nicotine replacement therapy (NRT) or electronic cigarettes: never, ever, prior to pregnancy, and during pregnancy up to 18 weeks and from 18 weeks to 34 weeks \[[@C16]\]. Background characteristics and history of previous and present pregnancies were obtained from the 18-week questionnaire and a brief interview at enrolment. Whether the women reported the ultrasound-corrected gestational age or calculated gestational age from their last menstrual period is not known. Study personnel measured maternal weight and height at the 18-week inclusion visit. Pre-pregnancy weight was obtained by self-report rather than by objective measures.

Dedicated trained study personnel using a non-elastic measuring tape performed infant anthropometric measures within the first 24 h after delivery. We report the mean of two left upper arm circumference measures midway between the acromial and olecranon process, and the mean of three thoracic and abdominal circumference measures performed at end-expiration when possible. For the thoracic circumference measures we placed the lower part of the measuring tape in line with the most caudal part of the xyphoid process. For the abdominal circumference measures the lower end of the measuring tape was placed in line with the cranial part of the umbilicus. All values were recorded in centimetres with one decimal, and mean values were calculated and rounded when appropriate. Background for the methods used is described in the [supplementary material](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00255-2019.figures-only#fig-data-supplementary-materials). Birthweight, length (crown--heel) and head circumference as well as placenta weight was collected from the hospital records. Placenta was weighed and recorded by the midwives within 30 min of delivery according to hospital guidelines.

Outcomes, exposures and covariates {#s3a}
----------------------------------

The main outcome was birthweight (in grams). Secondary anthropometric outcomes were birth length, head circumference, thoracic circumference, abdominal circumference and left mid upper arm circumference (all in centimetres), while the ratios of abdominal circumference to head circumference, thoracic circumference to head circumference, thoracic circumference to abdominal circumference and finally birthweight to placenta weight were proportional size outcomes.

The main exposure variables were based on any use of snus and/or smoke in pregnancy categorised into never in pregnancy ("never"), snus alone in pregnancy ("snus only") and smoking including dual snus users in pregnancy ("smoke/dual"). To differentiate between early and late snus exposure, we also separated the snus only group into "snus only 18 weeks" and "snus only 34 weeks". Women who reported ever-use of snus and/or smoking before pregnancy were included in the never group representing never-use during pregnancy. As only four women reported using NRT or electronic cigarettes, of whom three stopped when recognising pregnancy, they were included in the analyses based upon their use of snus and cigarette smoking.

Potential covariates were based upon factors previously shown to be associated with snus use in pregnancy \[[@C16]\] including maternal age, marital status, previous smoking history, *in utero* smoking exposure of the index women and living area. Additionally, we included factors possibly associated with birth size of the baby such as maternal education, pre-pregnancy body mass index (BMI), parity, fetal sex and gestational age at delivery (days). Further, as smoking cessation during pregnancy may cause weight gain \[[@C30], [@C31]\], we performed sensitivity analyses including adjustment for maternal gestational weight gain from pre-pregnancy to 18 weeks of pregnancy. The gestational age was based on femur length obtained at the routine second trimester ultrasound, as described previously \[[@C29]\].

Statistical analysis {#s3b}
--------------------

Categorical variables are presented as numbers and percentages, and continuous variables as means with standard deviation or 95% confidence intervals. Differences between categorical variables were analysed by Chi-squared test and numerical data by one-way ANOVA tests.

Associations between snus exposure and birth size outcomes were analysed using univariable and multivariable linear regression models with the birth outcomes as dependent variable and snus use as independent variable. The group of never snus users were defined as the reference group. In the multivariable models we included all covariates that were known potential confounders associated with snus use from our previous study \[[@C16]\] and the literature in general. Significant covariates with a p-value \<0.05 were kept in the final models, as appropriate for each outcome, with details given in [supplementary table S3](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00255-2019.figures-only#fig-data-supplementary-materials). Sensitivity analyses including adjustment for maternal gestational weight gain from pre-pregnancy to 18 weeks of pregnancy were performed in case of significant associations between snus use and the respective birth outcome.

The significance level was set to 5%. Because of low numbers of missing data we performed complete case analysis only. All analyses were performed using SPSS Statistics (version 25; IBM, Chicago, IL, USA).

Results {#s4}
=======

Most women (89.1%) reported never-use of tobacco products during pregnancy, while 150 (6.5%) reported snus only and 102 (4.4%) reported cigarette smoking, including 15 (0.6%) dual users. Up to 18 weeks of pregnancy 138 (6.0%) women used snus only at some time or current, and 12 (0.6%) up to 34 weeks. The majority (\>90%) of the snus and smoking/dual-using women stopped within pregnancy week six. Exposure to nicotine products was similar in term and preterm infants, as described in detail in the [supplementary material](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00255-2019.figures-only#fig-data-supplementary-materials) and [table S2](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00255-2019.figures-only#fig-data-supplementary-materials).

The exposure groups never, snus only and smoke/dual differed significantly from each other with respect to gestational age at birth, maternal age, maternal gestational weight gain, parity and socioeconomic factors, as listed in [table 1](#TB1){ref-type="table"}.

###### 

Background characteristics of the study population (n=2313) stratified by tobacco exposure during pregnancy

                                                **Subjects**   **Tobacco exposure during pregnancy**^\#^                            
  -------------------------------------------- -------------- ------------------------------------------- ------------ ------------ ---------
  **Subjects**                                      2313                      2061 (89.1)                  150 (6.5)    102 (4.4)   
  **Fetal sex male**                                                          1097 (53.0)                  73 (48.7)    50 (48.5)     0.37
  **Gestational age at birth**                      2274                                                                            
   Weeks                                                                       39.2±1.7                     39.6±1.7     38.9±1.7     0.001
   Days                                                                       274.7±11.6                   277.5±11.7   272.0±11.8    0.001
  **Placenta weight g**                             1740                       656±135.1                   679±110.2    643±144.9     0.12
  **Maternal factors**                                                                                                              
   Age years                                        2313                       32.6±4.1                     30.9±3.2     32.0±4.8    \<0.001
   Pre-pregnancy BMI                                2252                       23.1±3.6                     22.8±3.5     23.9±4.7     0.05
   BMI at 18 weeks                                  2278                       24.8±3.6                     24.8±3.6     25.8±4.8     0.016
   Weight pre-pregnancy kg                          2263                       65.4±11.1                   64.8±11.1    66.4±13.4     0.55
   Weight at inclusion kg                           2288                       70.1±11.1                   70.4±11.4    71.6±13.5     0.37
   Gestational weight gain up to 18 weeks kg        2259                        4.7±3.2                     5.4±3.5      5.3±3.8      0.002
  **Pregnancy history**                                                                                                             
   Current *in vitro* fertilisation                 2300                       173 (8.4)                    4 (2.7)      0 (0.0)     \<0.001
   Miscarriage(s) \<12 weeks                        2300                                                                              0.08
    0                                                                         1531 (74.3)                  126 (84.0)   73 (70.9)   
    1                                                                         371 (18.0)                   15 (10.0)    20 (19.4)   
    \>1                                                                        146 (7.1)                    9 (6.0)      10 (9.7)   
   Miscarriage(s)/stillbirths 12--23 weeks          2300                                                                              0.006
    0                                                                         2006 (97.9)                  148 (98.7)   96 (94.1)   
    1                                                                          41 (2.0)                     2 (1.3)      5 (4.9)    
    \>1                                                                         1 (0.0)                     0 (0.0)      1 (1.0)    
   Parity                                           2150                                                                              0.008
    0                                                                         1124 (59.2)                  107 (71.8)   59 (57.8)   
    1                                                                         612 (32.2)                   36 (24.2)    29 (28.4)   
    \>1                                                                        163 (8.6)                    6 (4.0)     14 (13.7)   
  **Sociodemographic factors**                                                                                                      
   Education                                        2141                                                                             \<0.001
    Preliminary school only                                                    13 (0.7)                     1 (0.7)      2 (2.0)    
    High school only                                                           175 (9.3)                   19 (12.8)    25 (24.5)   
    Higher education \<4 years                                                580 (30.7)                   60 (40.5)    42 (41.2)   
    Higher education ≥4 years                                                 1122 (59.3)                  67 (45.3)    33 (32.4)   
    Other                                                                       1 (0.1)                     1 (0.7)      0 (0.0)    
   Country of origin                                2150                                                                              0.005
    Norway and Sweden                                                         1683 (88.6)                  144 (96.6)   87 (85.3)   
    Rest of the world                                                         216 (11.4)                    5 (3.4)     15 (14.7)   
   Marital status                                   2150                                                                             \<0.001
    Married                                                                   816 (43.0)                   39 (26.2)    30 (29.4)   
    Cohabitants                                                               1037 (54.6)                  107 (71.8)   66 (64.7)   
    Single                                                                     30 (1.6)                     2 (1.3)      5 (4.9)    
    Divorced/separated                                                          1 (0.1)                     0 (0.0)      0 (0.0)    
    Other                                                                      15 (0.8)                     1 (0.7)      1 (1.0)    
   Living area                                      2150                                                                              0.026
    City, densely populated                                                   716 (37.7)                   76 (51.0)    42 (41.2)   
    City, less densely populated                                              732 (38.5)                   52 (34.9)    33 (32.4)   
    Suburb                                                                    311 (16.4)                   15 (10.1)    17 (16.7)   
    Countryside, village                                                       100 (5.3)                    5 (3.4)      5 (4.9)    
    Countryside, outside village                                               40 (2.1)                     1 (0.7)      5 (4.9)    
   Household income                                 2150                                                                             \<0.001
    Low                                                                        18 (0.9)                     3 (2.0)      4 (3.9)    
    Middle                                                                    991 (52.2)                   87 (58.4)    72 (70.6)   
    High                                                                      857 (45.1)                   57 (38.3)    24 (23.5)   
    Not reported                                                               33 (1.7)                     2 (1.3)      2 (2.0)    
  **Smoking history**                                                                                                               
   Previous smoking                                 2150                      300 (14.6)                   75 (50.0)    100 (98.0)   \<0.001
   *In utero* exposure to cigarette smoke           2150                                                                             \<0.001
    No                                                                        1463 (77.0)                  87 (58.4)    73 (71.6)   
    Yes                                                                       256 (13.5)                   29 (19.5)    21 (20.6)   
    Do not know                                                                180 (9.5)                   33 (22.1)     8 (7.8)    

Data are presented as n, n (%) or mean±[sd]{.smallcaps}, unless otherwise stated. BMI: body mass index. ^\#^: includes four females who answered "yes" to ever-use of other nicotine products (nicotine replacement therapy or electronic cigarettes); one was a daily user during pregnancy at 18 weeks and three quit when recognising pregnancy.

Unadjusted analyses showed no significant difference in birthweight among the women who used snus only compared to never and smoke/dual users ([table 2](#TB2){ref-type="table"}). We observed significantly higher birthweight in infants exposed to snus only up to 18 weeks ([table 3](#TB3){ref-type="table"}) after adjusting for parity, gestational age at birth, fetal sex, pre-pregnancy BMI and maternal age in multivariable regression analyses. However, after adjusting for maternal gestational weight gain (from pre-pregnancy to gestational week 18), the associations were no longer statistically significant in sensitivity analyses ([table 3](#TB3){ref-type="table"}). We found no significant interaction between gestational weight gain and the tobacco exposure groups.

###### 

Anthropometric measures and proportional size are given by tobacco exposure groups for 2313 newborn infants

                                           **Subjects**   **Tobacco exposure during pregnancy**^\#^                                          
  --------------------------------------- -------------- ------------------------------------------- ------------------- ------------------- -------
  **Anthropometric measures**                                            2061 (89.1)                      150 (6.5)           102 (4.4)      
   Birthweight g                               2252                   3577 (3556--5598)               3662 (3591--3733)   3575 (3472--3678)   0.11
   Length cm                                   2181                   50.5 (50.4--50.6)               50.8 (50.4--51.1)   50.4 (49.9--50.9)   0.26
   Head circumference cm                       2238                   35.2 (35.1--35.3)               35.5 (35.3--35.8)   35.3 (34.9--35.6)   0.029
   Thoracic  circumference cm                  2157                   34.0 (33.9--34.1)               34.2 (33.9--34.5)   34.2 (33.7--34.7)   0.30
   Abdominal  circumference cm                 2156                   32.8 (32.7--32.8)               32.9 (32.5--33.3)   32.7 (32.2--33.2)   0.79
   Left mid upper arm  circumference cm        2166                   11.1 (11.1--11.2)               11.3 (11.2--11.5)   11.2 (11.0--11.4)   0.15
  **Proportional size**                                                                                                                      
   Abdominal/head  circumference               2102                   0.94 (0.93--0.94)               0.92 (0.92--0.94)   0.93 (0.91--0.94)   0.45
   Thoracic/abdominal  circumference           2151                  1.04 (1.037--1.04)               1.04 (1.04--1.05)   1.05 (1.04--1.06)   0.14
   Thoracic/head  circumference                2103                  0.97 (0.965--0.97)               0.96 (0.96--0.97)   0.97 (0.96--0.98)   0.68
   Birthweight/placenta  weight                1729                    5.6 (5.5--5.7)                  5.5 (5.4--5.7)      5.7 (5.5--6.0)     0.54

Data are presented as n (%), n or mean (95% CI), unless otherwise stated. The reference group "never" includes all females who did not report use of tobacco or nicotine during pregnancy. The "smoke/dual" group includes dual smokers and snus users during pregnancy. Most of these subjects (\>90%) quit snus use or smoking by 6 weeks of pregnancy. ^\#^: includes four females who answered "yes" to ever-use of other nicotine products (nicotine replacement therapy or electronic cigarettes); one was a daily user during pregnancy at 18 weeks and three quit when recognising pregnancy.

###### 

Linear regression analyses: effect of tobacco exposure during pregnancy on birthweight (grams)

                                **Univariable**   **Multivariable^\#^ (1--5)**   **Univariable sensitivity analyses**   **Multivariable sensitivity analyses (1--6)**                                                                                                        
  ---------------------------- ----------------- ------------------------------ -------------------------------------- ----------------------------------------------- ----------------------- ------- ------ ----------------------- ------- ------ ----------------------- -------
  **Tobacco exposure**                                                                          0.085                                                                                           0.113                                  0.110                                  0.550
   Never                             1772                     Ref.                                                                          1772                                Ref.                    1694           Ref.                    1694           Ref.           
   Snus only                          143              91.3 (10.1--172.5)                                                                    143                          78.1 (4.7--151.5)             137      88.8 (5.6--172.0)             137     36.3 (−37.4--110.0)   
   Smoke/dual                         97              −6.5 (−103.9--90.9)                                                                    97                          11.0 (−76.6--98.6)              90     −5.0 (−106.4--96.4)             90    −20.1 (−109.1--68.9)   
  **Tobacco exposure**                                                                          0.120                                                                                           0.032                                  0.180                                  0.250
   Never                             1772                     Ref.                                                                          1772                                Ref.                    1694           Ref.                    1694           Ref.           
   Snus only up to  18 weeks          132             102.0 (17.7--186.3)                                                                    132                         100.0 (23.9--176.1)            127     96.8 (10.6--183.0)             127     53.8 (−22.6--130.1)   
   Snus only up to  34 weeks          11             −36.4 (−318.9--246.1)                                                                   11                         −183.1 (−436.5--70.3)            10    −13.1 (−310.3--284.1)            10    −180.6 (−440.6--79.5)  
   Smoke/dual                         97              −6.5 (−103.9--90.9)                                                                    97                          10.9 (−76.7--98.4)              90     −5.0 (−106.4--96.4)             90    −20.0 (−108.9--69.0)   

The reference group "never" includes all females who did not report use of tobacco or nicotine during pregnancy. The "smoke/dual" group includes dual smokers and snus users during pregnancy, of whom most quit before 6 weeks of pregnancy. The nonsignificant global p-values for snus-only and smoke/dual indicate that no significant associations were observed with birthweight. Covariates used in multivariable analyses: 1=parity, 2=gestational age at birth, 3=fetal sex, 4=pre-pregnancy body mass index, 5=maternal age, 6=gestational weight gain up to 18 weeks of pregnancy. Ref.: reference value. ^\#^: the results of the multivariable analyses restricted by the same study population as in the sensitivity analyses without adjusting for gestational weight gain, were similar in both populations (data not shown).

For the "snus up to 34 weeks" group, there was a nonsignificant trend of decreased birthweight.

The only other anthropometric measure with significant associations to snus exposure in unadjusted ([table 2](#TB2){ref-type="table"}) and adjusted regression analyses ([supplementary table S4](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00255-2019.figures-only#fig-data-supplementary-materials)) was head circumference. However, after adjusting for maternal gestational weight gain (from pre-pregnancy to gestational week 18) in sensitivity analyses, the association was no longer significant. We found no other significant associations between snus exposure in the univariable or multivariable regression analyses on anthropometric ([supplementary table S4](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00255-2019.figures-only#fig-data-supplementary-materials)) or proportional size outcomes ([supplementary table S5](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00255-2019.figures-only#fig-data-supplementary-materials)).

Discussion {#s5}
==========

In our cohort, in which 90% of the women stopped snus use at recognised pregnancy, snus exposure was not significantly associated with birthweight or other anthropometric or proportional size measures.

To our knowledge, this is the first prospective mother--child cohort study showing that the use of snus in pregnancy was not associated with infant birth size. Our results are supported by registry studies showing that women who quit snus early in pregnancy had the same risk of SGA or low birthweight of the baby as non-snus users \[[@C28], [@C32]\]. This is in contrast to an Indian cohort study of 1217 women interviewed during months 3--7 of pregnancy at house-to-house visits showing an average of 105 g lower birthweight among the 17% reporting daily use of chewable tobacco for ≥6 months \[[@C27]\]. However, there are important differences between the studies in regards to types of smokeless tobacco products, prevalence of exposures as well as probable cultural and sociodemographic differences. In view of the presumably low total *in utero* nicotine exposure in our study, with most women stopping in early pregnancy, our findings are in line with other studies showing that early cessation attenuates the effects of snus \[[@C32]\] or smoking \[[@C7]\].

The apparently higher birthweight in infants born to mothers using snus up to 18 weeks of pregnancy only, before adjusting for maternal weight gain, is in contrast to registry studies from Sweden, where nonsignificant reductions in birthweight were observed in sibling analyses \[[@C28]\]. However, sensitivity analyses showed that the significantly higher maternal gestational weight gain in those stopping snus use compared to non-users largely explained the difference in the model not adjusting for weight gain. We are unaware of studies including maternal gestational weight gain in their adjusted models, but propose that maternal gestational weight gain should be included in analyses exploring potential effects of nicotine exposure *in utero* on fetal growth. This is supported by studies showing an increased risk of excess gestational weight gain from pre-pregnancy to delivery when quitting smoking in pregnancy compared to non-smokers \[[@C30], [@C31]\] and substantially lower rate of neonatal birthweight below the 10th percentile \[[@C33]\]. However, we are unaware of studies on maternal gestational weight gain after snus cessation during pregnancy.

We were unable to conclude on the effects of continuous snus exposure through pregnancy up to 34 weeks, with only 11 subjects in this exposure group. Thus, the potential effect of continued use of snus throughout pregnancy is still uncertain. We did see a nonsignificant trend of decreased birthweight in this group, which is in line with the Indian study of smokeless tobacco \[[@C27]\], as well as in conventional \[[@C32]\], but not in sibling analyses in the Swedish birth registry study \[[@C26]\].

To our knowledge, this is the first study to investigate the potential effect of snus exposure in pregnancy on anthropometric and proportional size measures at birth. Birth size is determined by genetic predisposition and by the intrauterine environment, including potential unfavourable *in utero* exposures affecting fetal growth \[[@C34]\]. While birthweight and length are predictors of lean mass \[[@C35]\], abdominal circumference may indicate level of fat and/or size of the liver \[[@C34]\], and upper mid arm circumference predicts muscle mass \[[@C36]\]. Our study with predominantly early transient exposure to snus was not able to replicate the adverse effects on differential fetal growth by exposure to cigarette smoke \[[@C2], [@C3], [@C10]\].

The study is strengthened by the prospective design, specifically designed questionnaires completed at 18 and 34 weeks of pregnancy with detailed information on the use of products containing nicotine during pregnancy and time of cessation specified by 2-week intervals. The study provides standardised detailed anthropometric measurements conducted by trained study personnel within the first 24 h after delivery.

The high early pregnancy cessation rates of both snus use and cigarette smoking in this study is clearly positive for maternal and infant health, but limited our ability to study the effects of persistent use during pregnancy. Nevertheless, it provides important information for pregnant women who have stopped using snus or are planning to quit, as well as for health professionals providing their prenatal care, that early exposure does not seem to affect the birth size of the baby. In addition, detailed information of frequency of use and number of snus portions and/or cigarettes smoked among those who stopped when recognising their pregnancies are lacking, thus limiting the possibilities to assess dose--response effects. Our data are based on self-reports with no objective validation of nicotine or cotinine levels during pregnancy. Nevertheless, studies have shown that self-reports represent valid markers for tobacco exposure \[[@C37], [@C38]\]. There is uncertainty regarding the exact pregnancy week of self-reported cessation, as we do not know if the subjects reported the ultrasound corrected gestational age or the calculated gestational age from the last menstrual period. If the reported gestational age was the latter, the first two pregnancy weeks correspond with the last 2 weeks before conception, thus nicotine exposure to the offspring might be limited. The gestational age was determined based upon the routine ultrasound examination, as described in the [supplementary material](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00255-2019.figures-only#fig-data-supplementary-materials), with a potential variation that could not be accounted for in the present analyses. Additionally, we only adjust for weight gain in the first 18 weeks of pregnancy, since we do not have weight of the mothers at delivery. However, since most women stopped using snus by pregnancy week six, one might assume the weight gain effect related to cessation might be in the period up to 18 weeks of pregnancy. Although the participants were recruited from a nonselected general population, the educational level in our study was higher than in the Norwegian general population \[[@C29]\]. However, this is unlikely to impact the prevalence of snus use, since we have recently found that educational level is not associated with snus use during pregnancy \[[@C16]\]. It might affect the choice of lifestyle and diet, potentially influencing fetal growth. As this is a prospective cohort study, nonparticipation cannot be associated with the outcome. Therefore, effect estimates of snus use on birth outcomes should not be biased \[[@C39]\]. Potential covariates such as pre-eclampsia, gestational diabetes or other relevant maternal diseases that possibly could explain birth size were unavailable at the time of analyses.

Conclusion {#s5a}
----------

Maternal snus use in pregnancy, with most subjects stopping when knowing about their pregnancy, was not significantly associated with birthweight or anthropometric or proportional size measures of the newborn infants. Due to low prevalence of snus users up to 34 weeks of gestation, we could not conclude on potential effects of continued snus exposure in pregnancy on infant birth size.
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